Ader R (2003) Conditioned immunomodulation: research needs and directions. Brain Behav Immun 17: S51-S57.
Adler LJ, Gyulai FE, Diehl DJ, Mintun MA, Winter PM, Firestone LL (1997) Regional brain activity changes associated with fentanyl analgesia elucidated by positron emission tomography. Anesth Analg 84: 120-126.
Akil H, Watson S, Young E, Lewis M, Khachaturian H, Walker J (1984) Endogenous opioids: biology and function. Annu Rev Neurosci 7: 223-255.
Allport A (1989) Visual attention. In: Foundations of cognitive science (Posner MI, ed). Cambridge, MA: MIT.
Amanzio M, Benedetti F (1999) Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci 19: 484-494.
Andrews G (2001) Placebo response in depression: bane of research, boon to therapy. Br J Psychiatry 178: 192-194.
Apkarian AV, Sosa Y, Sonty S, Levy RM, Harden RN, Parrish TB, Gitelman DR (2004) Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci 24: 10410-10415.
Bao S, Chan VT, Merzenich MM (2001) Cortical remodeling induced by activity of ventral tegmental dopamine neurons. Nature 412: 79-83.
Barsky AJ, Saintfort R, Rogers MP, Borus JF (2002) Nonspecific medication side effects and the nocebo phenomenon. JAMA 287: 622-627.
Bencherif B, Fuchs PN, Sheth R, Dannals RF, Campbell JN, Frost JJ (2002) Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET). Pain 99: 589-598.
Benedetti F (1996) The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64: 535-543.
Benedetti F (1997) Cholecystokinin type-A and type-B receptors and their modulation of opioid analgesia. News Physiol Sci 12: 263-268.
Benedetti F, Amanzio M, Maggi G (1995) Potentiation of placebo analgesia by proglumide. Lancet 346: 1231.
Benedetti F, Amanzio M, Baldi S, Casadio C, Maggi G (1999a) Inducing placebo respiratory depressant responses in humans via opioid receptors. Eur J Neurosci 11: 625-631.
Benedetti F, Arduino C, Amanzio M (1999b) Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci 19: 3639-3648.
Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I (2003) Conscious expectation and unconscious conditioning in analgesic, motor and hormonal placebo/nocebo responses. J Neurosci 23: 4315-4323.
Benedetti F, Colloca L, Torre E, Lanotte M, Melcarne A, Pesare M, Bergamasco B, Lopiano L (2004) Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci 7: 587-588.
Bishop S, Duncan J, Brett M, Lawrence AD (2004) Prefrontal cortical function and anxiety: controlling attention to threat-related stimuli. Nat Neurosci 7: 184-188.
Blier P (2001) Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci [Suppl] 26: S3-S10.
Bragin EO, Yeliseeva ZV, Vasilenko GF, Meizerov EE, Chuvin BT, Durinyan RA (1984) Cortical projections to the periaqueductal grey in the cat: a retrograde horseradish peroxidase study. Neurosci Lett 51: 271-275.
Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S (2001) Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy. Arch Gen Psychiatry 58: 631-640.
Casey K, Svensson P, Morrow T, Raz J, Jone C, Minoshima S (2000) Selective opiate modulation of nociceptive processing in the human brain. J Neurophysiol 84: 525-533.
Colloca L, Benedetti F (2005) Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 6: 545-552.
Colloca L, Lopiano L, Lanotte M, Benedetti F (2004) Overt versus covert treatment for pain, anxiety and Parkinson's disease. Lancet Neurol 3: 679-684.
Craig AD, Chen K, Bandy D, Reiman EM (2000) Thermosensory activation of insular cortex. Nat Neurosci 3: 184-190.
de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293: 1164-1166.
DeRubeis RJ, Gelfand LA, Tang TZ, Simons AD (1999) Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 156: 1007-1013.
DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC (2005) Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 62: 409-416.
Desimone R, Duncan J (1995) Neural mechanisms of selective visual attention. Annu Rev Neurosci 18: 193-222.
Drolet G, Dumont EC, Gosselin I, Kinkead R, Laforest S, Trottier JF (2001) Role of endogenous opioid system in the regulation of the stress response. Prog Neuropsychopharmacol Biol Psychiatry 25: 729-741.
Duman RS, Malberg J, Thome J (1999) Neural plasticity to stress and anti-depressant treatment. Biol Psychiatry 19: 1181-1191.
Enserink M (1999) Can the placebo be the cure? Science 284: 238-240.
Fields H (2004) State-dependent opioid control of pain. Nat Rev Neurosci 5: 565-575.
Filliol D, Ghozland S, Chluba J, Martin M, Matthes H, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, Le MM, Valverde O, Maldonado R, Kieffer B (2000) Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25: 195-200.
Finniss DG, Benedetti F (2005) Mechanisms of the placebo response and their impact on clinical trails and clinical practice. Pain 114: 3-6.
Firestone L, Gyulai F, Mintun M, Adler L, Urso K, Winter P (1996) Human brain activity response to fentanyl imaged by positron emission tomography. Anesth Analg 82: 1247-1251.
Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ (1990) Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47: 1093-1099.
Freo U, Ori C, Dam M, Merico A, Pizzolato G (2000) Effects of acute and chronic treatment with fluoxetine on regional glucose cerebral metabolism in rats: implications for clinical therapies. Brain Res 854: 35-41.
Gabilondo A, Meana J, Garcia-Sevilla J (1995) Increased density of muopioid receptors in the postmortem brain of suicide victims. Brain Res 682: 245-250.
Geers AL, Helfer SG, Kosbab K, Weiland PE, Landry SJ (2005) Reconsidering the role of personality in placebo effects: dispositional optimism, situational expectations, and the placebo response. J Psychosom Res 58: 121-127.
Goebel MU, Trebst AE, Steiner J, Xie YF, Exton MS, Frede S, Canbay AE, Michel MC, Heemann U, Schedlowski M (2002) Behavioral conditioning of immunosuppression is possible in humans. FASEB J 16: 1869-1873.
Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, Mayberg H (2004) Modulation of cortical-limbic pathways in major depression: treatment specific effects of cognitive behavior therapy compared to paroxetine. Arch Gen Psychiatry 61: 34-41.
Gracely RH, Dubner R, Wolskee PJ, Deeter WR (1983) Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature 306: 264-265.
Grevert P, Albert L, Goldstein A (1983) Partial antagonism of placebo analgesia by naloxone. Pain 16: 129-143.
Gross-Isseroff R, Dillon K, Israeli M, Biegon A (1990) Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Res 530: 312-316.
Gunstad J, Suhr JA (2001) "Expectation as etiology" versus "the good old days": postconcussion syndrome symptom reporting in athletes, headache sufferers, and depressed individuals. J Int Neuropsychol Soc 7: 323-333.
Handy TC, Green V, Klein RM, Mangun GR (2001) Combined expectancies: event-related potentials reveal the early benefits of spatial attention that are obscured by reaction time measures. J Exp Psychol Hum Percept Perform 27: 303-317.
Hrobjartsson A, Gotzsche PC (2001) Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344: 1594-1602.
Hrobjartsson A, Gotzsche PC (2004) Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 256: 91-100.
Hyman SE, Nestler EJ (1996) Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 153: 151-162.
Ikemoto S, Panksepp J (1999) The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Rev 31: 6-41.
Kalin N, Shelton S, Barksdale C (1988) Opiate modulation of separation-induced distress in non-human primates. Brain Res 440: 285-292.
Khan A, Warner HA, Brown WA (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database. Arch Gen Psychiatry 57: 311-317.
Kienle GS, Kiene H (1997) The powerful placebo effect: fact or fiction? J Clin Epidemiol 50: 1311-1318.
Kirsch I, Sapirstein G (1998) Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention and treatment, Vol I, article 0002a, available at http://journals.apa.org/prevention/volume1/pre0010002a.html.
Knutson B, Cooper JC (2005) Functional magnetic resonance imaging of reward prediction. Curr Opin Neurol 18: 411-417.
Koerselman F, Laman DM, van Duijn H, van Duijn MA, Willems MA (2004) A 3-month, follow-up, randomized, placebo-controlled study of repetitive transcranial magnetic stimulation in depression. J Clin Psychiatry 65: 1323-1328.
Lazarus RS (1991) Cognition and motivation in emotion. Am Psychol 46: 352-367.
Levesque J, Eugene F, Joanette Y, Paquette V, Mensour B, Beaudoin G, Leroux JM, Bourgouin P, Beauregard M (2003) Neural circuitry underlying voluntary suppression of sadness. Biol Psychiatry 53: 502-510.
Levine JD, Gordon NC (1984) Influence of the method of drug administration on analgesic response. Nature 312: 755-756.
Levine JD, Gordon NC, Fields HL (1978) The mechanisms of placebo analgesia. Lancet 2: 654-657.
Lieberman MD, Jarcho JM, Berman S, Naliboff BD, Suyenobu BY, Mandelkern M, Mayer EA (2004) The neural correlates of placebo effects: a disruption account. NeuroImage 22: 447-455.
Lieberman MD, Hariri A, Jarcho JM, Eisenberger NI, Bookheimer SY (2005) An fMRI investigation of race-related amygdala activity in African-American and Caucasian-American individuals. Nat Neurosci 8: 720-722.
Lipman JJ, Miller BE, Mays KS, Miller MN North WC, Byrne WL (1990) Peak B endorphin concentration in cerebrospinal fluid: reduced in chronic pain patients and increased during the placebo response. Psychopharmacology 102: 112-116.
Ma QP, Han JS (1991) Neurochemical studies on the mesolimbic circuitry of antinociception. Brain Res 566: 95-102.
Martin SD, Martin E, Rai SS, Richardson MA, Royall R (2001) Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride. Arch Gen Psychiatry 58: 641-664.
Mayberg HS (2003) Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 65: 193-207.
Mayberg HS, Brannan SK, Mahurin RK, McGinnin S, Silva JA, Tekell JL, Jerabek PA, Martin CC, Fox PT (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48: 830-843.
Mayberg HS, Silva JA, Brannan SK, Tekell JL, McGinnis S, Mahurin RK, Jerabek PA (2002) The functional neuroanatomy of the placebo effect. Am J Psych 159: 728-737.
McGrath PJ, Stewart JW, Petkova E, Quitki FM, Amsterdam JD, Fawcett J, Reimherr FW, Rosenbaum JF, Beasley CM (2000) Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry 61: 518-524.
Melzack R, Wall PD (1965) Pain mechanisms: a new theory. Science 150: 971-979.
Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24: 167-202.
Moles A, Kieffer BL, D'Amato FR (2004) Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science 304: 1983-1986.
Montgomery SA (1996) Efficacy in long term treatment of depression. J Clin Psychiatry 57: 24-30.
Nelson EE, Panksepp J (1998) Brain substrates of infant-mother attachment: contributions of opioids, oxytocin, and norepinephrine. Neurosci Biobehav Rev 22: 437-452.
Ochsner KN, Bunge SA, Gross JJ, Gabrieli JD (2002) Rethinking feelings: an FMRI study of the cognitive regulation of emotion. J Cogn Neurosci 14: 1215-1229.
Ochsner KN, Ray RD, Cooper JC, Robertson ER, Chopra S, Gabrieli JD, Gross JJ (2004) For better or for worse: neural systems supporting the cognitive down- and up-regulation of negative emotion. NeuroImage 23: 483-499.
Pagnin D, de Queiroz V, Pini S, Cassano GB (2004) Efficacy of ECT in depression: a meta-analytic review. J ECT 20: 13-20.
Petrovic P, Ingvar M (2002) Imaging cognitive modulation of pain processing. Pain 95: 1-5.
Petrovic P, Kalso E, Petersson KM, Ingvar M (2002) Placebo and opioid analgesia—imaging a shared neuronal network. Science 295: 1737-1740.
Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M (2005) Placebo in emotional processing—induced expectations of anxiety relief activate a generalized modulatory network. Neuron 46: 957-969.
Phan KL, Fitzgerald DA, Nathan PJ, Moore GJ, Uhde TW, Tancer ME (2005) Neural substrates for voluntary suppression of negative affect: a functional magnetic resonance imaging study. Biol Psychiatry 57: 210-219.
Phelps EA, O'Connor KJ, Gatenby JC, Gore JC, Grillon C, Davis M (2001) Activation of the left amygdala to a cognitive representation of fear. Nat Neurosci 4: 437-441.
Pollo A, Torre E, Lopiano L, Rizzone M, Lanotte M, Cavanna A, Bergamasco B, Benedetti F (2002) Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. NeuroReport 13: 1383-1386.
Pollo A, Vighetti S, Rainero I, Benedetti F (2003) Placebo analgesia and the heart. Pain 102: 125-133.
Posner MI (1980) Orienting of attention. Q J Exp Psychol 32: 3-25.
Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS (1999) An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 83: 147-156.
Quitkin FM, Klein DF (2000) What conditions are necessary to assess anti-depressant efficacy? Arch Gen Psychiatry 57: 323-324.
Quitkin FRM, Rabkin JG, Gerald J, Davis JM, Klein DF (2000) Validity of clinical trails of antidepressants. Am J Psychiatry 157: 327-337.
Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC (1997) Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 277: 968-971.
Rizvi TA, Ennis M, Shipley MT (1992) Reciprocal connections between the medial preoptic area and the midbrain periaqueductal gray in rat: a WGA-HRP and PHA-L study. J Comp Neurol 315: 1-15.
Rubinstein M, Mogil JS, Japon M, Chan EC, Allen RG, Low MJ (1996) Absence of opioid stress-induced analgesia in mice lacking 
-endorphin by site directed mutagenesis. Proc Natl Acad Sci USA 93: 3995-4000.
Schlaepfer T, Strain E, Greenberg B, Preston K, Lancaster E, Bigelow G, Barta P, Pearlson G (1998) Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry 155: 470-473.
Schultz W (2002) Getting formal with dopamine and reward. Neuron 36: 241-263.
Schultz W, Tremblay L, Hollerman JR (2000) Reward processing in primate orbitofrontal cortex and basal ganglia. Cereb Cortex 10: 272-278.
Singer T, Seymour B, O'Doherty J, Kaube H, Dolan RJ, Frith CD (2004) Empathy for pain involves the affective but not sensory components of pain. Science 303: 1157-1162.
Smith Y, Zubieta J, Del Carmen M, Dannals R, Ravert H, Zacur H, Frost J (1998) Brain mu opioid receptor measurements by positron emission tomography in normal cycling women: relationship to LH pulsatility and gonadal steroid hormones. J Clin Endocrinol Metab 83: 4498-4505.
Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR (1997) Opiate receptor knockout mice define µ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94: 1544-1549.
Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P (1998) Use of pattern analysis to predict differential relapse on fluoxetine and placebo during continuation/maintenance treatment. Arch Gen Psychiatry 55: 334-343.
Vaidya VA, Duman RS (2001) Depresssion—emerging insights from neurobiology. Br Med Bull 57: 61-79.
Vase L, Robinson ME, Verne GN, Price DD (2003) The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 105: 17-25.
Volkow ND, Wang G-J, Ma Y, Fowler JS, Zhu W, Maynard L, Telang F, Vaska P, Ding Y-S, Wong C, Swanson JM (2003) Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 23: 11461-11468.
Wager TD, Smith EE (2003) Neuroimaging studies of working memory: a meta-analysis. Cogn Affect Behav Neurosci 3: 255-274.
Wager TD, Feldman Barrett L (2004) From affect to control: functional specialization of the insula in motivation and regulation. PsycExtra, available at http://www.psycinfo.com/psycextra/.
Wager TD, Phan KL, Liberzon I, Taylor SF (2003) Valence, gender, and lateralization of functional brain anatomy in emotion: a meta-analysis of findings from neuroimaging. NeuroImage 19: 513-531.
Wager TD, Reading S, Jonides J (2004a) Neuroimaging studies of shifting attention: a meta-analysis. NeuroImage 22: 1679-1693.
Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, Kosslyn SM, Rose RM, Cohen JD (2004b) Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303: 1162-1167.
Wagner KJ, Willoch F, Kochs EF, Siessmeier T, Tolle TR, Schwaiger M, Bartenstein P (2001) Dose-dependent regional cerebral blood flow changes during remifentanil infusion in humans: a positron emission tomography study. Anesthesiology 94: 732-739.
Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840-1847.
Watkins L, Mayer D (1982) Organization of endogenous opiate and nonopiate pain control systems. Science 216: 1185-1192.
Zhang S, Tang JS, Yuan B, Jia H (1998) Inhibitory effects of electrical stimulation of ventrolateral orbital cortex on the rat jaw-opening reflex. Brain Res 813: 359-366.
Zhang YQ, Tang JS, Yuan B, Jia H (1997) Inhibitory effects of electrically evoked activation of ventrolateral orbital cortex on the tail-flick reflex are mediated by periaqueductal gray in rats. Pain 72: 127-135.
Zubieta JK, Smith Y, Bueller J, Xu Y, Kilbourn M, Meyer C, Koeppe R, Stohler C (2001) Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293: 311-315.
Zubieta JK, Smith Y, Bueller J, Xu Y, Woike T, Kilbourn M, Meyer C, Koeppe R, Stohler C (2002) µ-Opioid receptor mediated antinociception differs in men and women. J Neurosci 22: 5100-5107.
Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA, Koeppe RA (2003a) Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 60: 1145-1153.
Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D (2003b) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299: 1240-1243.
Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, Stohler CS (2005a) Placebo effects mediated by endogenous opioid neurotransmission and µ-opioid receptors. J Neurosci 25: 7754-7762.
Zubieta JK, Yau WY, Scott DJ, Stohler CS (2005b) Belief or need? Accounting for individual variations in the neurochemistry of the placebo effect. Brain Behav Immun, in press.
Answers to all your Biology Questions
